Levi & Korsinsky investigates Syros Pharmaceuticals for halted Phase 2 trial and 61% stock drop.

Levi & Korsinsky investigates Syros Pharmaceuticals (SYRS) after the company's Aug 12, 2024 announcement to halt enrollment in Phase 2 clinical trial, SELECT-AML-1, due to low probability of success. Stock price fell by 61% on Aug 13. Investors who suffered losses are invited to contact the firm for more info on potential legal action.

August 25, 2024
7 Articles

Further Reading